Research & Literature

The Association Between Bullous Pemphigoid and Neurological Disorders in A Selected Malaysian Population.

Kwan Z, Lai YN, Ch'ng CC, et al.

The Medical journal of Malaysia 2015; (70(2)):81-5.

The molecular architecture of hemidesmosomes, as revealed with super-resolution microscopy.

Nahidiazar L, Kreft M, van den Broek B, et al.

Journal of cell science 2015; (128(20)):3714-9 doi:10.1242/jcs.171892.

Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.

Mendonça FM, Martín-Gutierrez FJ, Ríos-Martín JJ, Camacho-Martinez F

Dermatology (Basel, Switzerland) 2016; (232(2)):249-53 doi:10.1159/000443330.

Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.

Ahmed AR, Shetty S, Kaveri S, Spigelman ZS

Journal of the American Academy of Dermatology 2016; (74(4)):700-8.e3.

Diagnostic value of immunohistochemistry on formalin-fixed, paraffin-embedded skin biopsy specimens for bullous pemphigoid.

Glauser S, Rutz M, Cazzaniga S, et al.

The British journal of dermatology 2016; (175(5)):988-993 doi:10.1111/bjd.14686.

Bullous pemphigoid successfully treated with omalizumab.

Gönül MZ, Keseroglu HO, Ergin C, et al.

Indian journal of dermatology, venereology and leprology 2016; (82(5)):577-9 doi:10.4103/0378-6323.183628.

Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.

Hashimoto T, Ohzono A, Teye K, et al.

The British journal of dermatology 2017; (177(1)):141-151 doi:10.1111/bjd.15114.

Evidence for a role of eosinophils in blister formation in bullous pemphigoid.

de Graauw E, Sitaru C, Horn M, et al.

Allergy 2017; (72(7)):1105-1113 doi:10.1111/all.13131.

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Williams HC, Wojnarowska F, Kirtschig G, et al.

Lancet (London, England) 2017; (389(10079)):1630-1638 doi:10.1016/S0140-6736(17)30560-3.

Bullous pemphigoid.

Bağcı IS, Horváth ON, Ruzicka T, Sárdy M

Autoimmunity reviews 2017; (16(5)):445-455 doi:10.1016/j.autrev.2017.03.010.

Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls.

Sim B, Fook-Chong S, Phoon YW, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(10)):1709-1714 doi:10.1111/jdv.14312.

An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.

Sticherling M, Franke A, Aberer E, et al.

The British journal of dermatology 2017; (177(5)):1299-1305 doi:10.1111/bjd.15649.

The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita.

Németh T, Virtic O, Sitaru C, Mócsai A

The Journal of investigative dermatology 2017; (137(10)):2131-2139 doi:10.1016/j.jid.2017.05.017.

T regulatory cells and other lymphocyte subsets in patients with bullous pemphigoid.

Gambichler T, Tsitlakidon A, Skrygan M, et al.

Clinical and experimental dermatology 2017; (42(6)):632-637 doi:10.1111/ced.13135.

Bullous pemphigoid and pemphigus vulgaris.

Kayani M, Aslam AM

BMJ (Clinical research ed.) 2017; (357()):j2169 doi:10.1136/bmj.j2169.

The association between bullous pemphigoid and neurological disorders: a systematic review.

Milani-Nejad N, Zhang M, Kaffenberger J

European journal of dermatology : EJD 2017; (27(5)):472-481 doi:10.1684/ejd.2017.3066.

Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin.

Goyal N, Rao R, Shenoi SD, et al.

Indian journal of dermatology, venereology and leprology 2017; (83(5)):550-555 doi:10.4103/ijdvl.IJDVL_678_16.

Eosinophils as putative therapeutic targets in bullous pemphigoid.

Simon D, Borradori L, Simon HU

Experimental dermatology 2017; (26(12)):1187-1192 doi:10.1111/exd.13416.

IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.

Freire PC, Muñoz CH, Stingl G

The British journal of dermatology 2017; (177(6)):1644-1653 doi:10.1111/bjd.15924.

Ethnic variations in the epidemiology of bullous pemphigoid in Israel.

Kridin K, Bergman R

International journal of dermatology 2018; (57(1)):34-39 doi:10.1111/ijd.13813.

Reflectance confocal microscopy and optical coherence tomography for the diagnosis of bullous pemphigoid and pemphigus and surrounding subclinical lesions.

Mandel VD, Cinotti E, Benati E, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(9)):1562-1569 doi:10.1111/jdv.14795.

Unilateral, localized bullous pemphigoid in a patient with chronic venous stasis.

Shi CR, Charrow A, Granter SR, et al.

JAAD case reports 2018; (4(2)):162-164 doi:10.1016/j.jdcr.2017.09.032.

Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.

Holtsche MM, Goletz S, van Beek N, et al.

The British journal of dermatology 2018; (179(4)):918-924 doi:10.1111/bjd.16553.

Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation.

Kridin K

The British journal of dermatology 2018; (179(5)):1141-1147 doi:10.1111/bjd.16679.

High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid.

Koga H, Teye K, Ishii N, et al.

Frontiers in medicine 2018; (5()):139 doi:10.3389/fmed.2018.00139.

The spectrum of histopathologic findings in pemphigoid: Avoiding diagnostic pitfalls.

Hodge BD, Roach J, Reserva JL, et al.

Journal of cutaneous pathology 2018; (45(11)):831-838 doi:10.1111/cup.13343.

Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption.

Hübner F, Kasperkiewicz M, Knuth-Rehr D, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2018; (16(9)):1109-1118 doi:10.1111/ddg.13642.

A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid.

Goletz S, Probst C, Komorowski L, et al.

The British journal of dermatology 2019; (180(1)):149-156 doi:10.1111/bjd.17202.

Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.

Emtenani S, Yuan H, Lin C, et al.

The British journal of dermatology 2019; (180(5)):1099-1106 doi:10.1111/bjd.17313.

Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.

Meijer JM, Diercks GFH, de Lang EWG, et al.

JAMA dermatology 2019; (155(2)):158-165 doi:10.1001/jamadermatol.2018.4390.

Actigraphy-measured nocturnal wrist movements and assessment of sleep quality in patients with bullous pemphigoid: a pilot case-control study.

Kalinska-Bienias A, Piotrowski T, Kowalczyk E, et al.

Clinical and experimental dermatology 2019; (44(7)):759-765 doi:10.1111/ced.13902.

Neurological disorders are associated with bullous pemphigoid.

Papakonstantinou E, Limberg MM, Gehring M, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(5)):925-929 doi:10.1111/jdv.15444.

Bullous pemphigoid.

Miyamoto D, Santi CG, Aoki V, Maruta CW

Anais brasileiros de dermatologia 2019; (94(2)):133-146 doi:10.1590/abd1806-4841.20199007.

Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.

Kamata A, Kurihara Y, Funakoshi T, et al.

The British journal of dermatology 2020; (182(5)):1221-1227 doi:10.1111/bjd.18364.

Treatment of refractory bullous pemphigoid with IFN-α-2b: A case report.

Wang T, Xu Y, Ren Y, Luo G

Dermatologic therapy 2020; (33(2)):e13080 doi:10.1111/dth.13080.

The use of BIOCHIP mosaics in diagnostics of bullous pemphigoid: Evaluation and comparison to conventional multistep procedures.

Adaszewska A, Kalińska-Bienias A, Jagielski P, et al.

Journal of cutaneous pathology 2020; (47(2)):121-127 doi:10.1111/cup.13591.

Spongiform pemphigoid: A case series of an uncommon histopathologic pattern.

Merton A, Wu YH

Journal of cutaneous pathology 2020; (47(4)):339-345 doi:10.1111/cup.13627.

Depression and Anxiety in Patients with Bullous Pemphigoid: Impact and Management Challenges.

Kluger N, Pankakoski A, Panelius J

Clinical, cosmetic and investigational dermatology 2020; (13()):73-76 doi:10.2147/CCID.S212984.

A Systematic Review of Drug-Induced Pemphigoid.

Verheyden MJ, Bilgic A, Murrell DF

Acta dermato-venereologica 2020; (100(15)):adv00224 doi:10.2340/00015555-3457.

Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.

Morris LM, Lewis HA, Cornelius LA, et al.

Journal of cutaneous pathology 2020; (47(8)):742-746 doi:10.1111/cup.13687.

Emerging treatments for bullous pemphigoid.

Garrido PM, QueiróS CS, Travassos AR, et al.

The Journal of dermatological treatment 2022; (33(2)):649-661 doi:10.1080/09546634.2020.1782325.

Association of bullous pemphigoid and comorbid health conditions: a case-control study.

Lee S, Rastogi S, Hsu DY, et al.

Archives of dermatological research 2021; (313(5)):327-332 doi:10.1007/s00403-020-02100-2.

Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study.

Karabay EA, Çerman AA, Altunay İK

Sisli Etfal Hastanesi tip bulteni 2018; (52(4)):302-306 doi:10.14744/SEMB.2018.55376.

Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

Chen J, Mao X, Zhao W, et al.

Frontiers in immunology 2020; (11()):1607 doi:10.3389/fimmu.2020.01607.

Bullous pemphigoid and renal graft rejection: is there a causative link?

Sartor E, Sernicola A, Silvestre C, et al.

European journal of dermatology : EJD 2020; (30(4)):441-442 doi:10.1684/ejd.2020.3837.

International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.

Masmoudi W, Vaillant M, Vassileva S, et al.

The British journal of dermatology 2021; (184(6)):1106-1112 doi:10.1111/bjd.19611.

Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt-split skin in Tehran, Iran.

Daneshpazhooh M, Fazlolahi S, Mahmoudi H, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(6)):e370-e372 doi:10.1111/jdv.17137.

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.

Lambadiari V, Kountouri A, Kousathana F, et al.

BMC endocrine disorders 2021; (21(1)):23 doi:10.1186/s12902-021-00689-7.

Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy.

Montagnon CM, Lehman JS, Murrell DF, et al.

Journal of the American Academy of Dermatology 2021; (85(1)):18-27 doi:10.1016/j.jaad.2020.05.161.

Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.

Montagnon CM, Tolkachjov SN, Murrell DF, et al.

Journal of the American Academy of Dermatology 2021; (85(1)):1-14 doi:10.1016/j.jaad.2020.11.076.

Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.

Didona D, Scarsella L, Fehresti M, et al.

Frontiers in immunology 2021; (12()):569287 doi:10.3389/fimmu.2021.569287.

Erythematous Plaques and Tense Bullae in an Infant.

Ederle A, Whisonant CT, Nymeyer H

Cureus 2021; (13(7)):e16623 doi:10.7759/cureus.16623.

Phototherapy with UVB-NB as a new adjuvant therapy for bullous pemphigoid: A pilot study.

Vassallo C, Pellico MR, Gherzi S, et al.

Photodermatology, photoimmunology & photomedicine 2022; (38(2)):169-172 doi:10.1111/phpp.12722.

The global incidence of bullous pemphigoid: a systematic review and meta-analysis.

Persson MSM, Begum N, Grainge MJ, et al.

The British journal of dermatology 2022; (186(3)):414-425 doi:10.1111/bjd.20743.

Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Zhou T, Peng B, Geng S

Frontiers in immunology 2021; (12()):718073 doi:10.3389/fimmu.2021.718073.

Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.

Zhang X, Sui D, Wang D, et al.

Frontiers in immunology 2021; (12()):731774 doi:10.3389/fimmu.2021.731774.

A Cross-Sectional Study to Correlate Disease Severity in Bullous Pemphigoid Patients with Serum Levels of Autoantibodies Against BP180 and BP230.

Muhammed N, Korgaonkar S, Pradhan V, Khopkar US

Indian dermatology online journal 2021; (12(5)):696-700 doi:10.4103/idoj.IDOJ_813_20.

Bullous Pemphigoid and Other Pemphigoid Dermatoses.

Pratasava V, Sahni VN, Suresh A, et al.

Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101061.

Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

Chen X, Zhang Y, Luo Z, et al.

PloS one 2022; (17(4)):e0264705 doi:10.1371/journal.pone.0264705.

Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study.

Martin E, Mauer I, Malzahn U, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2022; (20(6)):798-805 doi:10.1111/ddg.14738.

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

Borradori L, Van Beek N, Feliciani C, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(10)):1689-1704 doi:10.1111/jdv.18220.

Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study.

Dikmen HO, Yilmaz K, Benoit S, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(11)):2181-2189 doi:10.1111/jdv.18414.

Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination.

Shanshal M

Cureus 2022; (14(6)):e26383 doi:10.7759/cureus.26383.

A case of bullous pemphigoid induced by torsemide.

Wurtz P, Borucki R, Georgesen C

JAAD case reports 2022; (26()):95-97 doi:10.1016/j.jdcr.2022.06.023.

Association of Peripheral Blood and Cutaneous Eosinophils With Bullous Pemphigoid Disease Severity and Treatment Outcomes.

Garrido PM, Aguado-Lobo M, Espinosa-Lara P, et al.

Actas dermo-sifiliograficas 2022; (113(9)):T881-T887 doi:10.1016/j.ad.2022.05.025.

Survival and prognostic factors in bullous pemphigoid: A retrospective cohort study.

Papara C, Chiorean R, Leucuta DC, et al.

Indian journal of dermatology, venereology and leprology 2023; (89(3)):363-371.

Can Methotrexate Be Employed as Monotherapy for Bullous Pemphigoid? Analysis of Efficiency and Tolerance of Methotrexate Treatment in Patients with Bullous Pemphigoid.

Wojtczak M, Nolbrzak A, Woźniacka A, Żebrowska A

Journal of clinical medicine 2023; (12(4)) doi:10.3390/jcm12041638.

Evaluation of Dupilumab in Patients With Bullous Pemphigoid.

Zhao L, Wang Q, Liang G, et al.

JAMA dermatology 2023; (159(9)):953-960 doi:10.1001/jamadermatol.2023.2428.

Bilateral localized bullous pemphigoid in a young adult patient: A case report.

Nourmohammadpour P, Akhdar M, Ghanadan A, et al.

SAGE open medical case reports 2023; (11()):2050313X231190730 doi:10.1177/2050313X231190730.

Risk factors predisposing relapse of bullous pemphigoid at initial diagnosis: A retrospective cohort study of 205 patients.

Liu Y, Wang Y, Zhang J, et al.

International immunopharmacology 2023; (125(Pt A)):111082 doi:10.1016/j.intimp.2023.111082.

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.

de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, et al.

International journal of molecular sciences 2023; (24(23)) doi:10.3390/ijms242316786.

Occurrence of Bullous Pemphigoid in a Longstanding Case of Rheumatoid Arthritis in an Indian Patient: A Rare Association.

Deo KS, Chaurasia P, Sharma Y, et al.

Cureus 2024; (16(4)):e59226 doi:10.7759/cureus.59226.

Use of dupilumab for recalcitrant bullous pemphigoid: A case report.

Lamb J, Purdy K, Sutherland A

SAGE open medical case reports 2024; (12()):2050313X241274855 doi:10.1177/2050313X241274855.

Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.

Planella-Fontanillas N, Bosch-Amate X, Jiménez Antón A, et al.

The British journal of dermatology 2025; (192(3)):501-509 doi:10.1093/bjd/ljae403.

Bullous Pemphigoid Induced by Cefixime: A Rare Side Effect.

Sandakly N, El Koubayati G, Nassereddine H, Haddad F

Cureus 2024; (16(11)):e74246 doi:10.7759/cureus.74246.

Remote presentation of nivolumab-induced bullous pemphigoid in hepatocellular carcinoma.

Yoo A, Chen J, Sarma V, Arundel C

BMJ case reports 2025; (18(4)) doi:10.1136/bcr-2024-263285.